Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cancer|March 1, 1985
Survival following moderate-dose preoperative radiation therapy for carcinoma of the rectumP Friedmann, J L Garb, W C Park, et al.
British Journal of Pharmacology|October 21, 2016
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlationMengmeng Wang, Amanda K Kussrow, Mireia Fernandez Ocana, et al.
American Journal of Surgery|April 1, 1978
Adjuvant radiation therapy in colorectal carcinomaP Friedmann, W C Park, I I Afonya, et al.
Plos One|March 20, 2015
Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese miceYan Weng, Jeffrey R Chabot, Barbara Bernardo, et al.
Surgery, Gynecology & Obstetrics|March 1, 1987
Intestinal anastomosis after preoperative radiation therapy for carcinoma of the rectumP Friedmann, J L Garb, D P McCabe, et al.
Public Health Nursing (Boston, Mass.)|February 14, 2002
Dropping out of maternal and child home visitsLaVohn E Josten, Kay Savik, Melea R Anderson, et al.
Frontiers in Bioinformatics|October 28, 2022
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody ProgramsGeorgi I Kapitanov, Jeffrey R Chabot, Jatin Narula, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primatesAlbert M Kim, Veena R Somayaji, Jennifer Q Dong, et al.
AJR. American Journal of Roentgenology|November 1, 1992
The value of cerebral angiography in predicting cerebral ischemia during carotid endarterectomyR B Schwartz, K M Jones, G T LeClercq, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 2017
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical OutcomeJennifer Q Dong, James R Gosset, Odette A Fahmi, et al.
Pageof 4